Janux Therapeutics’ (JANX) “Outperform” Rating Reiterated at Wedbush

Wedbush reissued their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research report report published on Friday morning,RTT News reports. They currently have a $76.00 price target on the stock, up from their previous price target of $75.00.

Several other equities analysts have also recently issued reports on the company. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. BTIG Research lifted their target price on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a report on Wednesday, December 11th. Leerink Partners lifted their price objective on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a report on Tuesday, December 3rd. Finally, HC Wainwright boosted their price target on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $88.00.

Janux Therapeutics Stock Up 2.7 %

Shares of Janux Therapeutics stock opened at $32.89 on Friday. The stock has a market capitalization of $1.73 billion, a P/E ratio of -28.11 and a beta of 3.16. The stock has a 50 day moving average price of $43.75 and a two-hundred day moving average price of $47.81. Janux Therapeutics has a 12-month low of $31.69 and a 12-month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last issued its earnings results on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Sell-side analysts anticipate that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insiders Place Their Bets

In other Janux Therapeutics news, CEO David Alan Campbell sold 15,000 shares of Janux Therapeutics stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $67.00, for a total value of $1,005,000.00. Following the transaction, the chief executive officer now directly owns 242,054 shares of the company’s stock, valued at approximately $16,217,618. The trade was a 5.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total transaction of $140,994.86. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at $3,473,658.31. This represents a 3.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,668 shares of company stock valued at $3,582,515 over the last 90 days. Insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Plato Investment Management Ltd raised its position in shares of Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company’s stock worth $54,000 after purchasing an additional 187 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company’s stock worth $54,000 after buying an additional 442 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Janux Therapeutics in the 4th quarter valued at $59,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Janux Therapeutics by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after purchasing an additional 339 shares in the last quarter. Finally, Avanza Fonder AB purchased a new position in shares of Janux Therapeutics in the 4th quarter valued at $139,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.